Portfolio Performance (Crispr, Microvision, Hive Blockchain)

Here are some metrics and notes on the portfolio. The portfolio reflects the performance of the resources available executing the mission of KDK Fund.  

Security/Project	Type of Investment	Date of Investment Purchase	Cost of Investment	Current Value of Investment	Return %
Crispr Therapeutics	Stock	3/23/2020	$38.78	54.01	39.27%
Microvision	Stock	3/23/2020	$0.18	0.25	38.89%
Hive Blockchain	Stock	4/16/2020	$0.16	0.23	43.75%

Week's Notes

- Crispr Therapeutics - will likely be announcing earnings on April 27th.

- Hive Blockchain - Bitcoin halving in May 2020 (definition of halvening through Gemini Capital found here).

- Microvision - Company shareholder meeting on May 19th, 2020 (link here).

- The fund will continue to look for opportunities to improve the fund. The next likely entry into the portfolio will be energy related.


**All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.

Hive Blockchain Added to Portfolio

Hive Blockchain shares have been added to the portfolio.We currently feel that with the current resources available, this is the right move to be in the blockchain space. Hive Blockchain has the management experience, the existence in a growing market, and access to resources needed to build wealth for its stakeholders. The plan is to hold and likely add shares to the portfolio going forward. 

From the company's website - Simply put, HIVE is a cryptocurrency mining firm. We validate transactions on blockchain networks — like Ethereum — for rewards paid in cryptocurrencies. Everyday HIVE earns new crypto coins which it can monetize for revenue and cash flow. HIVE offers shareholders exposure to the operating margins from cryptocurrency mining plus a growing portfolio of coins.


KDK Fund looks to provide capital (financial, consulting, etc.) resources to companies and projects it deems are improving life's existence. The portfolio also has an equity stake in Crispr Therapeutics (post here), and Microvision (post here).  


 **All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.